Phosphate binders are medications used to reduce the absorption of phosphate and taken with meals and snacks. They are typically used in people with chronic kidney failure (CKF) as they often have difficulty getting rid of the phosphates that get into their blood (i.e., the serum phosphate in chronic kidney failure is typically elevated).
For people with chronic kidney failure, controlling serum phosphate is important because it is associated with bone pathology and regulated together with serum calcium by the parathyroid hormone (PTH).
Mechanism of action
These agents work by binding to phosphate in the GI tract, thereby making it unavailable to the body for absorption. Hence, these drugs are usually taken with meals to bind any phosphate that may be present in the ingested food. Phosphate binders may be simple molecular entities (such as magnesium, aluminium, calcium, or lanthanum salts) that react with phosphate and form an insoluble compound. Phosphate binders such as sevelamer may also be polymeric structures which bind to phosphate and are then excreted.
With regard to phosphate binders, aluminium-containing compounds (such as aluminium hydroxide) are the least preferred because prolonged aluminium intake can cause encephalopathy and osteomalacia. If calcium is already being used as a supplement, additional calcium used as a phosphate binder may cause hypercalcemia and tissue-damaging calcinosis. One may avoid these adverse effects by using phosphate binders that do not contain calcium or aluminium as active ingredients, such as lanthanum carbonate or sevelamer.
Common phosphate binders
|Aluminum salts||Alucaps||Calcium free||Risk of aluminum toxicity|
|Basaljel||High binder efficiency regardless of pH||Requires frequent monitoring-extra cost|
|Moderate tablet burden|
|Calcium carbonate||Calcichew||Aluminum free||Calcium containing-potential risk of hypercalcemia and ectopic calcification|
|Titralac||Moderate binding efficacy||Parathyroid hormone oversuppression|
|Relatively low cost||Gastrointestinal side effects|
|Moderate tablet burden||Efficacy pH dependent|
|Calcium acetate||Lenal Ace||Aluminum free||Calcium containing-potential risk of hypercalcemia and ectopic calcification|
|PhosLo||Higher efficacy than calcichew/sevelamer||Parathyroid hormone oversuppression|
|Moderately cheap||Gastrointestinal side effects|
|Lower calcium load than calcium carbonate||Large tablets, nonchewable formulation|
|Sevelamer hydrochloride||Renagel||Aluminium and calcium free||Relatively costly|
|Renvela||No gastrointestinal absorption||High pill burden|
|Moderate efficacy||Large tablets, nonchewable formulation|
|Reduces total and low-density lipoprotein cholesterol||Gastrointestinal side effects|
|Binds fat-soluble vitamins|
|Lanthanum carbonate||Fosrenol||Aluminum and calcium free||Relatively costly|
|Minimal gastrointestinal absorption||Gastrointestinal side effects|
|High efficacy across full pH range|
|Low tablet burden|
- Calcium acetate/magnesium carbonate (Osvaren, Lenal Ace, Renepho)
- Burtis, C.A.; Ashwood, E.R. and Bruns, D.E. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 5th Edition. Elsevier. pp1552
- ^ Lederer E, Ouseph R, Erbeck K. Hyperphosphatemia, eMedicine.com, URL: http://www.emedicine.com/med/topic1097.htm, Accessed on July 14, 2005.
- ^ Spiegel, David M.; Farmer, Beverly; Smits, Gerard; Chonchol, Michel (2007). "Magnesium Carbonate is an Effective Phosphate Binder for Chronic Hemodialysis Patients: A Pilot Study". Journal of Renal Nutrition 17 (6): 416. doi:10.1053/j.jrn.2007.08.005. PMID 17971314.
- High Phosphate Control - Official Fosrenol Homepage*
- Phosphate Binders: What Are They And How Do They Work? - American Association of Kidney Patients*
- Phosphate Binders - National Kidney Foundation
- Phosphate Binders - Northwest Kidney Centers - a center that provides services for people with ESRD in the Seattle area.
- High Phosphate - Phosphorus Control - Information for healthcare professionals on the treatment and management of hyperphosphatemia
Common Phosphate Binders
- Hutchison, A. J.; Wilkie, M. (2012). "Use of magnesium as a drug in chronic kidney disease". Clinical Kidney Journal 5: i62. doi:10.1093/ndtplus/sfr168.
- Lanthanum - medlineplus.org
- Sevelamer - medlineplus.org
- Sevelamer - Renvela.com